Active Health Foods, Inc. (OTCPK:AHFD) agreed to acquire 100% stake in Bioidentical Hormones Inc. on June 8, 2022. Active Health acquired Bioidentical and its principal subsidiary, Australian Menopause Centre. In a separate transaction, Active Health has been approved by the Securities and Exchange Commission to commence a $20 million Regulation A public offering at $0.001 per share for 20 billion shares. Investors will receive a total of 10% of the Company, fully diluted, for $20 million, valuing the Company at $200 million.

Active Health Foods, Inc. (OTCPK:AHFD) cancelled the acquisition of Bioidentical Hormones Inc. on October 13, 2022. It was an express condition of the purchase agreement that Active Health Foods, Inc. implement a reverse-split of its shares and then issue 70,000,000 post-split shares to the Bioidentical Hormones Inc. shareholders. Active is not able to receive regulatory approval having not filed its 12/31/2014 annual report or any quarterly reports in 2015 pursuant to Section 12 of the Exchange Act to implement the aforesaid reverse-split of its shares and therefore the parties have terminated their agreement.